During the 1960s, the non-selective inhibitor of both sodium-glucose cotransporter-1 (SGLT1) and SGLT2, known as phlorizin, drew interest as a possible treatment for diabetes [24,25]. The gene discussed is SLC5A2; the disease is diabetes mellitus.